SwanBio Makes its Case for Rare Neurological Disease Gene Therapy By Mark TerryMay 16, 2023 SwanBio Therapeutics, based in Philadelphia, issued a healthcare resource use study that confirmed the burden [….]
BioBuzz rounds up some of the top Philadelphia life sciences companies looking to strengthen their teams for the coming year. The companies offer multiple job listings in different departments for candidates with a wide range of skills and experience levels.
After yet another year with COVID-19, the Greater Philadelphia Alliance for Capital and Technology (PACT) knew Philly entrepreneurs needed a reason to celebrate, IRL.
PACT gathers industry leaders, growing companies and local institutions each year for its Enterprise Awards celebrating innovators in the tech and life sciences community. 2021’s event was the first back after a pandemic hiatus and honored investor and serial entrepreneur Josh Kopelman with a Legend Award.
This year, for its 29th edition, PACT convened folks at the Springfield Country Club in Delaware County on Tuesday, May 24, to honor 27 people and organizations. Though there was no Legend Award this time around, nine companies and people took home awards.
SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions, today announced the completion of a $56 million Series B financing round, led by founding investors Syncona Limited and Mass General Brigham Ventures. The new funding brings SwanBio’s total financing raised to date to $133 million.
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead candidate, SBT101. SBT101 is being investigated as a potential treatment for patients with adrenomyeloneuropathy (AMN). SwanBio plans to initiate a randomized, controlled Phase 1/2 clinical trial to assess the safety and efficacy of SBT101 in the second half of 2022.
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced that its Investigational New Drug (IND) application for its lead candidate, SBT101, for the treatment of adrenomyeloneuropathy (AMN), was cleared by the U.S. Food and Drug Administration (FDA).
